The short version of adipose tissue fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-23 and is reviewed periodically as new material appears.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
6-Monoacetylmorphine (6-MAM, 6-acetylmorphine, or 6-AM) is an opioid and also one of three active metabolites of heroin (diacetylmorphine), the others being morphine and the much less active 3-monoacetylmorphine (3-MAM).
=== Medical === Dihydromorphine is used for the management of moderate to severe pain such as that occurring in cancer; however, it is less effective in treating neuropathic pain and is generally considered inappropriate and ineffective for psychological pain.
As chronic obstructive pulmonary disease (COPD) advances, about 35% of patients experience severe weight loss called pulmonary cachexia, including diminished muscle mass. Around 25% experience moderate to severe weight loss, and most others have some weight loss. Greater weight loss is associated with poorer prognosis. Theories about contributing factors include appetite loss related to reduced activity, additional energy required for breathing, and the difficulty of eating with dyspnea (labored breathing). Cancer, a very common and sometimes fatal cause of unexplained (idiopathic) weight loss. About one-third of unintentional weight loss cases are secondary to malignancy. Cancers to suspect in patients with unexplained weight loss include gastrointestinal, prostate, hepatobiliary (hepatocellular carcinoma, pancreatic cancer), ovarian, hematologic or lung malignancies. People with HIV often experience weight loss, and it is associated with poorer outcomes. Wasting syndrome is an AIDS-defining condition. Gastrointestinal disorders are another common cause of unexplained weight loss – in fact they are the most common non-cancerous cause of idiopathic weight loss. Possible gastrointestinal etiologies of unexplained weight loss include: celiac disease, peptic ulcer disease, inflammatory bowel disease (crohn's disease and ulcerative colitis), pancreatitis, gastritis, diarrhea, chronic mesenteric ischemia and many other GI conditions. Infection. Some infectious diseases can cause weight loss.
== History == Trazodone was developed in Italy, in the 1960s, by Angelini Research Laboratories as a second-generation antidepressant. It was developed according to the mental pain hypothesis, which was postulated from studying patients and which proposes that major depression is associated with a decreased pain threshold. In sharp contrast to most other antidepressants available at the time of its development, trazodone showed minimal effects on muscarinic cholinergic receptors. Trazodone was patented and marketed in many countries all over the world, starting with Italy in 1972 and West Germany in 1977. It was approved by the Food and Drug Administration (FDA) in 1981 and was the first non-tricyclic or MAOI antidepressant approved in the US.
=== Multiple turns === In many cases, one or more residues are involved in two partially overlapping turns. For example, in a sequence of 5 residues, both residues 1 to 4 and residues 2 to 5 form a turn; in such a case, one speaks of an (i, i + 1) double turn. Multiple turns (up to sevenfold) occur commonly in proteins. Beta bend ribbons are a different type of multiple turn. Multiple types of short H-bonded loop motifs are composed of overlapping H-bonded turns of the same or different types (lengths), including the Schellman loop and its variants, the multiple types of the beta bulge loop, and others. These motifs, which play key roles in proteins, including as helix caps, chain-reversers in beta hairpins and ligand binders, have been described as "compound turns" and classified using a compact notation that specifies the types and start positions in the loop of each motif's turns. The ExploreTurns tool supports the exploration and analysis of these motifs. The tool may also be used to explore individual H-bonded turns of all types.
Sources: en.wikipedia.org
=== Livestock and crop predation === A limitation of food sources in early spring and wild berry and nut crop failures in summer may contribute to bears regularly feeding from human-based food sources. These bears often eat crops, especially during autumn hyperphagia when natural foods are scarce. Favored crops include apples, oats and corn. American black bears can do extensive damage in areas of the northwestern United States by stripping the bark from trees and feeding on the cambium. Livestock depredations occur mostly in spring. Although they occasionally hunt adult cattle and horses, they seem to prefer smaller prey such as sheep, goats, pigs and young calves. They usually kill by biting the neck and shoulders, though they may break the neck or back of the prey with blows with the paws. Evidence of a bear attack includes claw marks and is often found on the neck, back and shoulders of larger animals. Surplus killing of sheep and goats is common. American black bears have been known to frighten livestock herds over cliffs, causing injuries and death to many animals; whether this is intentional is not known. Occasionally bears kill pets, especially domestic dogs, which are most prone to harass a bear. It is not recommended to use unleashed dogs to deter bear attacks. Although large, aggressive dogs can sometimes cause a bear to run, if pressed, angry bears often turn the tables and end up chasing the dogs in return. A bear in pursuit of a pet dog can threaten both canid and human lives.
== Function == CENPA is a protein which epigenetically defines the position of the centromere on each chromosome, determining the position of kinetochore assembly and the final site of sister chromatid cohesion during mitosis. This proteins is frequently accompanied by "centrochromatin"-associated changes to canonical histones and is constitutively present in centromeres. The CENPA protein is a histone H3 variant which replaces one or both canonical H3 histones in a subset of nucleosomes within centromeric chromatin. CENPA has the greatest sequence divergence of the histone H3 variants, with just 48% similarity to canonical histone H3, and has a highly diverged N-terminal tail that lacks many well characterised histone modification sites including H3K4, H3K9 and H3K27. Unusually for a histone, CENPA nucleosomes are not loaded together with DNA replication and are loaded at different cell cycle stages in different organisms: G1 phase in human, M phase in drosophila, G2 in S. pombe. To orchestrate this specialised loading there are CENPA-specific histone chaperones: HJURP in human, CAL1 in drosophila, nefr-1 in C. elegans and Scm3 in S. pombe. In most eukaryotes CENPA is loaded into large domains of highly repetitive satellite DNA. The position of CENPA within satellite DNA are heritable at the protein level through a purely epigenetic mechanism. This means that the position of CENPA protein binding to the genome is copied upon cell division to the two daughter cells independent of the underlying DNA sequence.
When it was known as Boston Chicken, restaurants specialized in rotisserie chicken and a variety of side dishes, but in February 1995, the chain expanded its menu to include turkey, meatloaf, and ham and changed the name to Boston Market in the fall of 1995 to reflect this. The corporate name remained Boston Chicken, Inc. until 1997, when the new name became popular and the corporate name was changed to Boston Market Corporation. In 1995, Boston Chicken created the Einstein Bros. Bagels chain of bakery cafés, after acquiring several smaller chains of bagel-centric bakeries. In 1996, the chain launched "Boston Carver Sandwiches", which featured chicken, turkey, ham, and meatloaf; in 1997, due to the success of the sandwich line, "Extreme Carver" sandwiches, filled with larger portions of meat and cheese, were launched. The company raised a lot of debt to finance its expansion. The rapid expansion allowed the company to create a steady stream of revenue from one-time development fees and increasing royalties, but also raised interest rates on its development loans. In 1998, the company filed for Chapter 11 bankruptcy. Since April 1999, a selection of Boston Market-branded items have been available in many supermarkets across the United States. Boston Market was purchased by McDonald's Corporation in May 2000, primarily for its real estate holdings. McDonald's found the brand serviceable, and continued to operate and expand Boston Market. In the early 2000s, Boston Market operated two locations in Toronto, Ontario.
Generate:Biomedicines is a biotechnology company founded in 2018 and headquartered in Somerville, Massachusetts. It specializes in using machine learning to design and optimize proteins for therapeutic applications, with a focus on immunology, oncology, and infectious diseases.
Lorenzo Feritta, who at the time was one of the presidents of the UFC, said, "We want 100 percent of the fighters tested the night they compete". Also, in addition to the drug testing protocols in place for competitors on fight night, the UFC conducts additional testing for main event fighters or any fighters that are due to compete in championship matches. This includes enhanced, random 'out of competition' testing for performance-enhancing drugs, with both urine and blood samples being taken. The UFC also announced that all potential UFC signees would be subject to mandatory pre-contract screening for performance-enhancing drugs prior to being offered a contract with the promotion.
Sources: en.wikipedia.org
Soon after inoculation, yeast begin to rapidly consume the available assimilable nitrogen with up to 46% of YAN being fully consumed by the onset of full fermentation. Because inorganic nitrogen, such as the ammonium salts in DAP, are toxic to yeast in high levels, it is never added during inoculation when the biomass of the newly re-hydrated yeast is low. Many winemakers split up the dosage of DAP with the first addition being made at the end of the lag phase when the yeast enter their period of exponential growth and alcoholic fermentation begins. In most must this is around 48 to 72 hours after inoculation. A second dosage is then often added around a third of the way through sugar fermentation and often before the sugar levels hit 12-10 Brix (6.5 to 5.5 Baumé, 48.3 to 40.0 Oechsle) because as the fermentation progresses yeast cells are no longer able to bring the nitrogen into the cell due to the increasing toxicity of ethanol surrounding the cells. This leaves the nitrogen unused and available for spoilage organisms that may come afterwards.
Although all political control was officially vested in the People's Congresses, in reality Libya's existing political leadership continued to exercise varying degrees of power and influence. Debate remained limited, and major decisions regarding the economy and defence were avoided or dealt with cursorily; the GPC largely remained "a rubber stamp" for Gaddafi's policies. On rare occasions, the GPC opposed Gaddafi's suggestions, sometimes successfully; notably, when Gaddafi called on primary schools to be abolished, believing that homeschooling was healthier for children, the GPC rejected the idea. In other instances, Gaddafi pushed through laws without the GPC's support, such as when he desired to allow women into the armed forces. At other times, he ordered snap elections when it appeared that the GPC would enact laws he opposed. Gaddafi proclaimed that the People's Congresses provided for Libya's every political need, rendering other political organizations unnecessary; all non-authorized groups, including political parties, professional associations, independent trade unions, and women's groups, were banned. Despite these restrictions, Ronald Bruce St. John noted that the Jamahiriya system still "introduced a level of representation and participation hitherto unknown in Libya". With preceding legal institutions abolished, Gaddafi envisioned the Jamahiriya as following the Qur'an for legal guidance, adopting sharia law; he proclaimed "man-made" laws unnatural and dictatorial, only permitting Allah's law.
=== Sa–Sc === Margarita Salas (1938–2019). Spanish biochemist at the Spanish National Research Council. Known for work on DNA replication. First woman elected to the Royal Spanish Academy. Wolfram Saenger (1939–2026). German biochemist and protein crystallographer at the Free University of Berlin, known for work on membrane proteins and protein-nucleic acid complexes. Member Natl. Acad. Sci. USA Frederick Sanger FRS (1918–2013). British biochemist at Cambridge University, known for advances in sequencing proteins and nucleic acids. Nobel prizes in Chemistry (1958, 1980). Foreign Associate Natl. Acad. Sci. USA. Albert Schatz (1920–2005). American microbiologist and science educator at Temple University, the discoverer of the antibiotic streptomycin. Paul Schimmel (b. 1940). American biochemist at the Scripps Research Institute, who developed methods of nucleic acid sequencing and coauthored (with Charles Cantor) the very influential three-volume book Biophysical Chemistry. Member Natl. Acad. Sci. USA Rudolph Schoenheimer (1898–1941). German-American biochemist at Columbia, pioneer of radioactive tagging of molecules. Stefan Schuster (b. 1961). German biophysicist at the University of Jena, pioneer in metabolic control analysis and metabolic pathway analysis. Rose Scott-Moncrieff (1903–1991). British biochemical geneticist at the University of Cambridge.
==== Nitrogen ==== The nitrogen stable isotope system is based on the relative enrichment/depletion of 15N in comparison to 14N in δ15N. Carbon and nitrogen stable isotope analyses are complementary in paleodiet studies. Nitrogen isotopes in bone collagen are ultimately derived from dietary protein, while carbon can be contributed by protein, carbohydrate, or fat. δ13C values help distinguish between dietary protein and plant sources while systematic increases in δ15N values as you move up in trophic level helps determine the position of protein sources in the food web. 15N increases 3-4% with each trophic step upward. It has been suggested that the relative difference between human δ15N values and animal protein values scales with the proportion of that animal protein in the diet, though this interpretation has been questioned due to contradictory views on the impact of nitrogen intake through protein consumption and nitrogen loss through waste release on 15N enrichment in the body. Variations in nitrogen values within the same trophic level are also considered. Nitrogen variations in plants, for example, can be caused by plant-specific reliance on nitrogen gas which causes the plant to mirror atmospheric values. Enriched or higher δ15N values can be achieved in plants that grew in soil fertilized by animal waste. Nitrogen isotopes have been used to estimate the relative contributions of legumes verses nonlegumes, as well as terrestrial versus marine resources.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.